SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aster is a next-generation decentralized perpetual exchange that combines non-custodial trading with advanced features like hidden orders and multi-chain support. The platform emerged from the merger of Astherus and APX Finance in late 2024, with APX token holders able to migrate their holdings to ASTER.  Aster addresses the gap between centralized and decentralized exchanges by enabling traders to maintain full control of their assets while accessing deep liquidity and CEX-grade trading tools. The platform supports trading of both cryptocurrency perpetuals and U.S. stocks with up to 100x leverage, all settled on-chain in crypto without requiring traditional financial infrastructure.  The platform offers two distinct trading modes to accommodate different user needs. Simple Mode provides one-click, MEV-resistant trading with up to 1001x leverage for beginners, while Pro Mode delivers a full order book with advanced features like automated grid trading and hidden orders that remain invisible until execution.   Aster operates across BNB Chain, Ethereum, Solana, and Arbitrum without requiring bridging, with liquidity pooled across markets to support large trades with minimal slippage. A distinctive feature allows users to deposit yield-generating assets like asBNB or USDF as collateral, earning passive returns while trading, maximizing capital efficiency compared to platforms where collateral sits idle.  Aster received backing from YZi Labs (formerly Binance Labs), which holds a minority stake through a private fund managing over $10 billion on behalf of early Binance executives. Changpeng Zhao, founder of Binance, serves in an advisory role and has personally invested over $2.5 million worth of ASTER tokens.   The ASTER token serves multiple functions including governance rights, staking rewards through liquidity provision, and earning incentives through the platform's points program for traders and liquidity providers.

ASTERION

ASTER is trending due to a significant pump following public endorsements and reported personal purchases by CZ, Binance's founder, alongside news of its Robinhood listing. The community is sharply divided, with many anticipating substantial gains for this perpetual DEX, while others caution it's a pump-and-dump fueled by speculation.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community anticipates the upcoming 4/20 cultural moment and potential cannabis rescheduling, generating strong discussions around its 'culture first' mission. Enthusiasts rally around its goal to advance global cannabis legalization and integrate real-world utility, proclaiming it 'like Bitcoin but way higher' in vibes and purpose.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing extreme volatility after rapidly halting its new compounded GLP-1 weight-loss pill following FDA enforcement signals and a Department of Justice referral. The community is fiercely debating whether this regulatory setback spells disaster for the company or merely removes an overhang, creating a buying opportunity for its broader telehealth business amidst intense competition from big pharma.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction following the launch of its PYTH Reserve, which uses monthly network revenue for systematic token buybacks, and its expansion into institutional RWA price feeds. Community sentiment highlights Pyth's role as a leading oracle in the 'RWA next meta,' with many anticipating significant growth driven by its robust utility and revenue-based tokenomics.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is generating significant discussion following a recent insider share sale by its CEO that has fueled negative sentiment and contributed to stock volatility, while the community actively weighs rumors of a potential buyout and anticipates key pipeline updates, including for its Casgevy gene therapy, ahead of upcoming healthcare conferences.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is generating significant buzz due to new integrations and rapid user growth, positioning it as a potential Layer 1 powerhouse that is notably holding strong amidst broader crypto market turbulence, even as the community debates its tokenomics and long-term valuation.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as investors seek downside protection and hedge against a perceived overbought market, reflecting a bearish sentiment towards the Dow Jones Industrial Average amidst economic uncertainty. Its visibility is further amplified by significant online conversation around a popular cryptocurrency sharing the same ticker.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending due to strong Q4 earnings, an upbeat 2026 outlook, and a new agreement with the Department of War to significantly increase missile production, reinforcing its defense leadership. The community is actively discussing how this rally is driven by heightened global tensions and expectations for expanded defense budgets, despite recent volatility stemming from executive compensation and stock buyback critiques.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid a wave of analyst upgrades emphasizing its robust growth and position as a key AI infrastructure beneficiary, even as the software sector faces broader concerns about competition and AI disruption. The community is actively discussing whether the recent pullback presents a compelling buying opportunity for this cloud observability leader.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as preliminary Q4 results and robust 2026 Briumvi revenue guidance ignite optimism for its rapidly growing, best-in-class MS drug. The community is actively discussing its undervalued status and the increasing likelihood of a strategic buyout, especially given big pharma's patent cliff challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.

Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results

VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.

FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway

AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.

Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study

SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.

Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome 

RARE resubmits FDA filing for UX111 after CRL, adding long-term neurologic and biomarker data, with a Q3 2026 decision in sight.

Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 230.6% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug 

Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.

Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?

Here is how ADC Therapeutics SA (ADCT) and Assertio (ASRT) have performed compared to their sector so far this year.

Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet

The consensus price target hints at a 249.9% upside potential for Assertio (ASRT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$12.74
Prev Close	$11.62
Open	$11.69
Dividend Yield	0.00%
50-Day Moving Average	$10.95
Beta	1.31
Avg. Volume	51,781.20
PE Ratio	-2.70

52-Week High	$15.15
52-Week Low	$7.71
Market Capitalization	$81.75M
EPS (Annual)	-$3.40
Price to Book	0.77
Revenue Per Employee	$2.15M
Enterprise Value/EBITDA	N/A

ASRT
Assertio Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ASRT News

ASRTAssertio Holdings Inc